Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a novel virus which led to a pandemic. There is no approved treatment for coronavirus disease 2019 (COVID-19). Overtime, physicians understood that in some severe patients' glucocorticoids could be considered as a second line option.
Aim: Since there are a limited number of reports addressing the use of glucocorticoids (GCs) in patients with moderately severe COVID19, we decided to publish the results for patients who referred to our national team and received glucocorticoids as part of their medication.
Materials and Methods: This descriptive and prospective study included 35 clinically-diagnosed moderate to severe COVID-19, in outpatient and inpatient settings. Patients were received intravenous dexamethasone, oral prednisolone and pulsed methylprednisolone. Demographic, clinical signs and symptoms, laboratory and chest CT findings of patients were recorded.
Results: Men comprised 60% of this group of patients. Lymphocyte counts were depleted on admission in a majority group of patients (54.3%). Shortness of breath, O2 sat and respiratory rate improved on average 48 to 72 hours after administration of glucocorticoids. Almost all patients had favorable clinical courses during treatment with glucocorticoids. CT scan findings showed bilateral peripheral patchy infiltrations with ground glass opacities as the dominant pattern of lung involvement (60%). One patient was admitted to the intensive care unit.
Conclusion: The results of our study showed that the administration of Glucocorticoids in the early stages of COVID-19 disease is not only effective but also safe and prevents the progression of the disease.